Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Lloyds Banking Group Plc American Depositary Shares (LYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Lloyds Banking Group Plc American Depositary Shares — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Lloyds Banking Group Plc American Depositary Shares trades at $5.65 (market cap $79.07B). The key difference: Lloyds Banking Group Plc American Depositary Shares is far larger — about 8.9× Kymera Therapeutics Inc. Common Stock's market cap, and Lloyds Banking Group Plc American Depositary Shares pays a 3.96% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Lloyds Banking Group Plc American Depositary Shares for 3 Days on average.
| KYMR | LYG | |
|---|---|---|
Market Cap | $8.87B | $79.07B |
Volume | 779,107 | 20,385,611 |
Sector | Health | Financials |
52-Week High | $127.31 | $6.28 |
52-Week Low | $55.80 | $4.44 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $8.26B | $101.61B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lloyds Banking Group (LYG) trades at $5.50, up 0.73% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 24.5% and has beaten earnings estimates in two of the last three quarters. Recent news highlights its 2030 growth plan emphasizing AI and efficiency, with potential acquisition interest in Aldermore.
The outlook is mixed: analyst consensus is bullish (58% buy ratings), but technicals and a recent earnings miss pose near-term risks. Upside catalysts include strategic investments and resilient UK consumers, while risks involve economic sensitivity and competitive pressures. The stock's valuation appears reasonable with a P/E of 12.98.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Lloyds Banking Group Plc American Depositary Shares
Lloyds Banking Group provides retail, commercial, and insurance services in the United Kingdom. Its banking brands include Lloyds Bank, Halifax, and Bank of Scotland.
Read more on LYG →
